Affymetrix (Santa Clara, California) Introduces Axiom® miRNA Target Site Genotyping Arrays
Published: Nov 06, 2012
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) introduces Axiom® miRNA Target Site Genotyping Arrays, the only high-density genotyping tools for genome-wide evaluation of microRNA (miRNA) target sites. These new arrays will enable comprehensive studies to elucidate how genomic variation in miRNA regulatory machinery influences gene expression and disease risk. It interrogates 238,000 SNPs and indels in genes for all parts of the miRNA cascade including miRNAs, their mRNA target sites, and silencing machinery.